FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number 3235-0287 Estimated average burden hours per response: 0.5

obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] ZEIN YOUSSEF EL (Last) (First) (Middle) C/O IDERA PHARMACEUTICALS, INC. 167 SIDNEY STREET					2. Issuer Name and Ticker or Trading Symbol IDERA PHARMACEUTICALS, INC. [IDRA] 3. Date of Earliest Transaction (Month/Day/Year) 06/07/2017 4. If Amendment, Date of Original Filed (Month/Day/Year)									(Che	Relationship of Reporting Person(s) to Issuer Check all applicable) X Director Qfficer (give title below) Other (specify below)				wner specify
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)														Line >	 Form filed by One Reporting Person Form filed by More than One Reporting Person 				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day				•	ion 2A. Deemed Execution Date,			3. Transac Code (Ir 8) Code			(A) or (D) (A) or (D) (Price		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Dai if any (Month/Day/Y	ite, 4. C	ransact ode (In	tion	5. Num of Derivat Securit Acquir (A) or Dispos of (D) (Instr. : and 5)	iber tive ties ed sed	6. Date Exc Expiration (Month/Da	ercisa Date	able and	le and 7. Title and Amount of Securities Underlying Derivative Security (Instr and 4) Amor		3 unt	8. Price of Derivative Security (Instr. 5)	9. Number derivative e Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	0 F(D (1) (1) (1)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
				c	ode	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Num of Shar						
Stock Options ⁽¹⁾	\$1.63	06/07/2017			A		50,000		06/07/2018	(2) 0	6/07/2027	Commor Stock	50,0	000	\$ 0	50,000		D	

Explanation of Responses:

1. These options were granted pursuant to the Company's director compensation on the date of the Company's 2017 annual meeting of stockholders at an exercise price to the closing price of the Company's common stock on the date of grant.

2. These options will vest in full and become immediately exercisable on the first anniversary of the date of grant, subject to continued service as director, and are granted under the Company's 2013 Stock Incentive Plan, as amended.

06/08/2017 /s/ Youssef El Zein

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5